Results 81 to 90 of about 6,074 (204)

Bioengineered Extracellular Vesicles in Emerging Cancer Vaccine Platforms

open access: yesSmall Science, Volume 5, Issue 11, November 2025.
This review highlights recent advances in engineering extracellular vesicles (EVs) as next‐generation cancer vaccines. It outlines their biological roles and antigen‐presenting capacity, explores key strategies for antigen loading and delivery optimization, and summarizes preclinical and clinical applications using EVs from diverse immune and tumor ...
Wonkyung Ahn   +4 more
wiley   +1 more source

A Novel Therapeutic Strategy for the Treatment of Glioma, Combining Chemical and Molecular Targeting of Hsp90a [PDF]

open access: yes, 2011
Hsp90α's vital role in tumour survival and progression, together with its highly inducible expression profile in gliomas and its absence in normal tissue and cell lines validates it as a therapeutic target for glioma.
Adi Mehta   +55 more
core   +2 more sources

Gasdermins: multifunctional effectors of membrane permeabilization across cellular compartments

open access: yesThe FEBS Journal, Volume 292, Issue 22, Page 5899-5920, November 2025.
Gasdermins (GSDMs) are pore‐forming proteins best known for driving pyroptosis through plasma membrane (PM) permeabilization. Beyond triggering inflammatory cell death, GSDMs can also associate with organelle membranes, including mitochondria, lysosomes, ER, and nucleus, where they modulate membrane integrity and cellular signaling.
Eleonora Margheritis   +2 more
wiley   +1 more source

Therapeutic Effect of Targeting Branched-Chain Amino Acid Catabolic Flux in Pressure-Overload Induced Heart Failure. [PDF]

open access: yes, 2019
Background Branched-chain amino acid (BCAA) catabolic defect is an emerging metabolic hallmark in failing hearts in human and animal models. The therapeutic impact of targeting BCAA catabolic flux under pathological conditions remains understudied ...
Chen, Mengping   +8 more
core   +1 more source

The Hsp90β Isoform: An Attractive Target for Drug Development

open access: yesMedicinal Research Reviews, Volume 45, Issue 5, Page 1452-1465, September 2025.
ABSTRACT The beta isoform of 90 kDa heat shock protein (Hsp90β) plays a critical role in maintaining cellular proteostasis by assisting in the folding and refolding of proteins, which is essential for both normal cellular function and stress response.
Subhabrata Chaudhury   +2 more
wiley   +1 more source

Nematode CDC-37 and DNJ-13 form complexes and can interact with HSP-90

open access: yesScientific Reports, 2021
The molecular chaperones Hsc70 and Hsp90 are required for proteostasis control and specific folding of client proteins in eukaryotic and prokaryotic organisms.
Lukas Schmauder   +5 more
doaj   +1 more source

A phosphorylation of RIPK3 kinase initiates an intracellular apoptotic pathway that promotes prostaglandin2α-induced corpus luteum regression

open access: yeseLife, 2021
Receptor-interacting serine/threonine-protein kinase 3 (RIPK3) normally signals to necroptosis by phosphorylating MLKL. We report here that when the cellular RIPK3 chaperone Hsp90/CDC37 level is low, RIPK3 also signals to apoptosis.
Dianrong Li   +10 more
doaj   +1 more source

Antiangiogenic compounds: well-established drugs versus emerging natural molecules [PDF]

open access: yes, 2018
Angiogenesis is the natural and physiologic process of growing blood vessels from pre-existing ones. Pathological angiogenesis occurs when the precise balance of all the molecular pathways that regulate angiogenesis is disrupted, and this process is a ...
Abreu, Rui M.V.   +4 more
core   +1 more source

Identification and Characterization of Harc, a Novel Hsp90-associating Relative of Cdc37 [PDF]

open access: yesJournal of Biological Chemistry, 2001
Although little is known about the precise mechanisms by which the molecular chaperone Hsp90 recognizes its client proteins, Cdc37 has been shown to play a critical role in the targeting of Hsp90 to client protein kinases. Described here is the identification and characterization of a novel 35-kDa human protein that is 31% identical to Cdc37.
G M, Scholz, K, Cartledge, N E, Hall
openaire   +2 more sources

Emerging Target Discovery Strategies Drive the Decoding of Therapeutic Power of Natural Products and Further Drug Development: A Case Study of Celastrol

open access: yesExploration, Volume 5, Issue 4, August 2025.
Using celastrol as a case study, this review summarizes various target discovery strategies for natural products, including chemical proteomics, protein microarray, degradation‐based protein profiling, proteome‐wide label‐free approaches, network pharmacology, target‐based drug screening, and indirect strategies.
Yanbei Tu   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy